 |
|
 |
|
Ingredients>>
|
|
Standard Extracts>>
|
|
Ratio Extracts>>
|
 |
|
 |
|
 |
| You decide the competitiveness of the "living law"
|
|
You decide the competitiveness of the "living law"
Weihua, chairman of Beijing Pharmaceutical Group Prudential on the 25th at the eighth CHITEC 2005 China International Summit Forum on Chinese medicine, on China's pharmaceutical enterprises to build innovation system of the three contexts.
Weihua Cheng said, first of all, China is rapidly emerging innovation with enterprises as the social environment. Which is reflected in: Enterprise of the nature, scale change, the market mechanism maturing; government will encourage enterprises in all aspects of self-innovation and development; intellectual property rights, building a more complete system of laws; National R & D institutes, colleges and universities to speed up the reform of scientific research .
Secondly, the Chinese pharmaceutical enterprises of the living environment has been great changes have taken place, this will inevitably lead to companies determined to attach importance to independent innovation capacity-building and improve. Which is reflected in: general imitation of pharmaceutical production costs increased, the value of drugs down, profit margins narrowed; medical security system "wide coverage, low-security" the characteristics and market competition intensified, low-cost competition will become a means of survival of pharmaceutical enterprises ; domestic and international competition, domestic competition in the growing international phenomenon; time after the arrival of GMP, enterprises will rely on scientific and technological innovation and their own intellectual property rights to protect their products competitive edge in the market.
Third, China's pharmaceutical enterprises to develop innovative drugs facing some major difficulties. This is shown in the following: insufficient funds, no funds to engage in innovative research, resulting in a low-cost duplicate; current domestic pharmaceutical enterprises profitability and growth and innovation capability have not yet shown a high degree of correlation; new drug R & D inputs huge risk, but also do not have a reasonable risk of exit mechanism to solve the worries of investors, new drug R & D mode and high-tech achievements into mechanisms, venture capital mechanisms, tax incentives mechanisms and incentives, such as human resources are not effectively combine.
|
|
|
